Clinical Trials Browser

Phase 2 × Lung Neoplasms × Ramucirumab × Clear all

NCT04340882 2026-01-30

DoceRamPem

Phase 2 Active not recruiting

Lung Neoplasms

NCT06031688 2026-01-23

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05642572 2025-12-05

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04120454 2025-07-11

Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer

Phase 2 Completed

6 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04267913 2020-11-20

Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)

Phase 2 Withdrawn

Lung Neoplasms

NCT01160744 2019-09-13

A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

280 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms